Results 1 to 10 of about 25,328 (173)

PACIFIC-5: A Phase III Clinical Trial of Consolidation Durvalumab in Patients With Unresectable Stage III NSCLC and No Progression After Concurrent or Sequential Chemoradiotherapy

Journal of Hematology and Oncology
Background Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC).
Lin Wu, Dongqing Lv, Yi-Long Wu
exaly   +2 more sources

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

JTO Clinical and Research Reports, 2021
Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse events (AEs) remains unknown ...
Narek Shaverdian, MD, Michael Offin, MD, Annemarie F. Shepherd, MD, Matthew D. Hellmann, MD, Daniel R. Gomez, MD, Jamie E. Chaft, MD, Andreas Rimner, MD   +6 more
doaj   +1 more source

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Clinical and Translational Radiation Oncology, 2023
Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended.
Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri   +5 more
doaj   +1 more source

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Thoracic Cancer, 2022
Background Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC).
Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Alvin Wong, Folefac Aminkeng, Yvonne Ang, Yugarajah Asokumaran, Jia Li Low, Matilda Lee, Joan R. E. Choo, Gloria Chan, Adrian Kee, Sen Hee Tay, Boon Cher Goh, Ross A. Soo   +14 more
doaj   +1 more source

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma

Scientific Reports, 2021
This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory (RR) multiple myeloma (MM ...
Mary H. Young, Greg Pietz, Elizabeth Whalen, Wilbert Copeland, Ethan Thompson, Brian A. Fox, Kathryn J. Newhall   +6 more
doaj   +1 more source

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Cost Effectiveness and Resource Allocation, 2023
Background Durvalumab plus gemcitabine and cisplatin has a significant clinical benefit for advanced biliary tract cancer (BTC). However, the high price of durvalumab warrants an exploration of the economics.
Qiuling Zhao, Ruixiang Xie, Wanfu Zhong, Wenbin Liu, Ting Chen, Xiuliang Qiu, Lin Yang   +6 more
doaj   +1 more source

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

Thoracic Cancer, 2022
Objective Compare outcomes in patients with stage III non–small cell lung cancer (NSCLC) treated with chemoradiation and adjuvant durvalumab to historical controls treated with chemoradiation alone.
Akram Saad, Jeffrey Goldstein, Sarit Appel, Sameh Daher, Damien Urban, Amir Onn, Hadas Gantz‐Sorotsky, Anastasiya Lobachov, Teodor Gottfried, Benjamin Spieler, Jair Bar   +10 more
doaj   +1 more source

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

Therapeutic Advances in Medical Oncology, 2022
Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Yosuke Miyamoto, Toshihide Yokoyama, Chiaki Matsumoto, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki   +32 more
doaj   +1 more source

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Cancer Reports, 2023
Background Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies.
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie‐Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig   +19 more
doaj   +1 more source

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

Cancer Medicine, 2022
Background Agents targeting the programmed cell death‐1 pathway have demonstrated encouraging activity across multiple solid tumor types. The dose expansion phase of this phase I study evaluated the safety, tolerability, and antitumor activity of ...
Yuichiro Doki, Makoto Ueno, Chih‐Hung Hsu, Do‐Youn Oh, Keunchil Park, Noboru Yamamoto, Tatsuya Ioka, Hiroki Hara, Manabu Hayama, Masahiro Nii, Keiko Komuro, Mariko Sugimoto, Makoto Tahara   +12 more
doaj   +1 more source